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Background: The hepatic resection for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)
which is not uncommon at clinic continues to be debated. Our study introduced a novel classification of HCC with
PVTT and compared the outcomes of surgical treatment between different groups.
Methods: From January 2008 to December 2012, a total of 56 cases of HCC with PVTT underwent liver resection
combined with thrombectomy. Clinical pathological features and surgical data of these patients were retrospectively
studied. The patients were divided into two groups. Cumulative overall and disease-free survival curves of the patients
were compared according to different groups.
Results: Sixteen patients (28.6%) belonging to group A were compared to 40 patients (71.4%) belonging to group B.
The rates of capsular formation and tumor number showed differences between the two groups (P = 0.047, P = 0.032).
Group A had more liver cirrhosis than group B (P = 0.047). The patients with large blood loss (≥1,000) were more in
group A, as well. There was no significant difference in complications between the two groups except the ascites
(P = 0.028). The 1-year overall survival rate of group A after liver resection was 31.5%. The 1-, 3-, and 5-year overall
survival rates of group B were 62.3%, 16.1%, and 5.2%, respectively. For further study, group B had significantly
better overall survival than group A (P = 0.033). Group A had significantly higher incidence of recurrence than
group B (P = 0.021).
Conclusions: Liver resection combined with thrombectomy for HCC with PVTT can get better outcome in the HCC
patients with PVTT involving only one branch (left/right) of portal vein (group B) compared to patients with PVTT
involving the main portal vein trunk or both the left and right portal veins (group A).
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide which ranks as the
second leading cause of cancer death among males [1-4].
In China, HCC ranks as the second most frequent cause
of cancer death in males [5-7]. Despite the progress in
surgical techniques, the prognosis of HCC especially
HCC with portal vein tumor thrombus (PVTT) remains
unsatisfactory. PVTT is one of the most significant factors
for poor prognosis. The median survival of untreated HCC* Correspondence: zjxujiangfeng@hotmail.com
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unless otherwise stated.with PVTT was reported to be 2.7 months. The treatment
to the HCC with PVTT is still controversial [8-11].
Although liver resection combined with thrombectomy
was considered to be a valid therapeutic technique for
these patients, the efficiency of surgical treatment for HCC
with PVTT still remains to be evaluated [12-15].Methods
From January 2008 to December 2012, 56 patients with
HCC complicated by PVTT underwent hepatic resection
combined with thrombectomy at the Affiliated Hospital
of Zhejiang University, School of Medicine, Hangzhou,
China. Clinical pathological features and surgical data of
these patients were retrospectively studied. Databaseis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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were divided into two groups: group A, tumor thrombi
involving the main portal vein trunk or both the left and
right portal veins and group B, tumor thrombi involving
only one branch (left or right) of portal vein. Cumulative
overall survival curves of patients were compared
according to the different groups. All patients had
preoperative evaluation including blood biochemistry, chest
radiography, liver and renal function tests, ultrasonography,
and computed tomography.
Liver resection was undertaken in the presence of
good cardiopulmonary and renal function, Pugh-Child’s
grades A or B, no ascites, tumor confined to one side of
the liver, and no evidence of extrahepatic metastasis.
Usually, we reserve the remnant liver volume more
than 50% in the cirrhosis patients and 35% to 40% in
noncirrhosis patients. Hepatic inflow occlusion was
used routinely by Pringle’s maneuver. The liver resection
was combined with the extraction of tumor thrombus
through the broken ends of portal vein or by opening the
trunk of portal vein. Any small PVTT in the tiny branches
was suctioned. All intraoperative and postoperative
complications were recorded retrospectively. Follow-up
after surgery included AFP level and ultrasonography
(or CT scan).
Our research was in compliance with the Helsinki
Declaration. Our research have been performed with the
approval of the ethics committee of the fourth Affiliated
Hospital of Zhejiang University, School of Medicine.
Continuous variables are expressed as mean ± SD and
compared using the independent samples t test. Overall
survival was calculated by using the Kaplan-Meier survival
method and compared using the log-rank test. All statistical
analyses were performed using statistical software (SPSS
13.0 for Windows, SPSS, Chicago, IL, USA). P < 0.05 was
considered to be statistically significant.Figure 1 Different classifications of PVTT. (A), (B), and (C) belong to gro
main portal vein trunk, the left portal vein and the right portal vein; (B) tum
involving both the left and right portal veins; (D) tumor thrombi involving
only the left branch of portal vein. PV, portal vein; PVTT, portal vein tumorResults
Clinicopathologic features of 56 HCC patients with PVTT
Sixteen patients (28.6%) belonging to group A were
compared to 40 patients (71.4%) belonging to group B.
The new classification for HCC with PVTT was shown
in Figure 1. The clinical and pathologic parameters of
the two groups were shown in Table 1. There were 10
patients (62.5%) that had positive hepatitis B in group A
compared to 26 patients (65%) in group B. Thirteen
patients (81.2%) had liver cirrhosis in group A while in
group B, only 21 patients (52.5%) had liver cirrhosis.
Group A had significantly more liver cirrhosis patients
than in group B (P = 0.047). The rates of capsular formation
and tumor number showed differences between two groups
(P = 0.047, P = 0.032). The capsular formation in group A
was 18.8% compared to 47.5% in group B. The tumor size
in group A was 6.5 ± 5.0 while in group B, it was 5.3 ± 4.3.
Intraoperative and postoperative data of 56 HCC patients
with PVTT
Intraoperative and postoperative data including major
complications of 56 HCC patients with PVTT are shown
in Table 2. Although there was no significant difference
between the two groups in the time for hepatectomy and
time for inflow occlusion (P = 0.595, P = 563), the patients
with large blood loss (≥1,000) were more in group A than
in group B (P = 0.042). The only hospital death was caused
by uncontrolled bleeding. The hospital stay in group A was
15 ± 6 days compared to 14 ± 7 days in group B. There was
no significant difference in complications between the two
groups except the ascites (P = 0.028).
Overall and disease-free survival curves of the different
groups of HCC patients with PVTT
The 1-year overall survival rate of group A after liver
resection was 31.5%. The 1-, 3-, and 5-year overall survivalup A; (D) and (E) belong to group B. (A) Tumor thrombi involving the
or thrombi involving the main portal vein trunk; (C) tumor thrombi
only the right branch of portal vein; and (E) tumor thrombi involving
thrombus.
Table 1 Clinicopathologic features of 56 HCC patients
with PVTT
Variables Group A (n = 16) Group B (n = 40) P value
Gender 0.588
Female 3 (18.8%) 8 (20%)
Male 13 (81.2%) 32 (80%)
Age (years) 0.785
< 60 14 (87.5%) 36 (90%)
≥ 60 2 (12.5%) 4 (10%)
Hepatitis B status 0.860
Negative 6 (37.5%) 14 (35%)
Positive 10 (62.5%) 26 (65%)
Capsular formation 0.047
Presence 3 (18.8%) 19 (47.5%)
Absence 13 (81.2%) 21 (52.5%)
Tumor number 0.032
Solitary 2 (12.5%) 17 (35%)
Multiple 14 (87.5%) 23 (65%)
AFP level 0.797
Negative 7 (43.7%) 16 (40%)
Positive 9 (56.3%) 24 (60%)
Liver cirrhosis 0.047
Absent 3 (18.8%) 19 (47.5%)
Present 13 (81.2%) 21 (52.5%)
Child-Pugh classification 0.633
A 11 (68.7%) 30 (75%)
B 5 (31.3%) 10 (25%)
Tumor size (cm) 6.5 ± 5.0 5.3 ± 4.3 0.453
Italicized texts mean P < 0.05.







Time for hepatectomy (min) 165 ± 60 156 ± 55 0.595
Time for inflow occlusion (min) 10.5 ± 9.5 11.3 ± 8.8 0.563
Blood loss 0.042
< 1,000 4 (37.5%) 22 (55%)
≥ 1,000 12 (62.5%) 18 (45%)
Blood transfusion (ml) 0.122
Without 4 (25%) 19 (47.5%)
With 12 (75%) 21 (52.5%)
Hospital death 1 (6.25%) 0 0.111
Hospital stay (days) 15 ± 6 14 ± 7 0.392
Major complications 4 (25%) 8 (20%) 0.680
Ascites 2 0 0.028
Wound infection 0 2 0.273
Pulmonary infection 0 2 0.273
Biliary fistula 0 1 0.460
Liver failure 0 1 0.460
Bleeding 2 2 0.386
Italicized texts mean P < 0.05.
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For further study, group B have significantly better overall
survival than group A (P = 0.033). Group A had sig-
nificantly higher incidence of recurrence than group B
(P = 0.021) (Figure 2). We also investigated the recur-
rence pattern in the two groups (Additional file 1:
Table S1). There was no significant difference in recur-
rence pattern between the two groups (P = 0.876).
Furthermore, we investigated the overall survival curves of
the subgroups according to Figure 1 (Figure 3). There
was no significant difference between group A, group
B, and group C (P = 0.675). Similarly, there was no
significant difference between group D and group E
(P = 0.383).
Discussion
PVTT has been proven to have significant relation with
HCC metastasis and recurrence after hepatectomy. HCC
with PVTT was often considered to be advanced andthe treatment for these patients remains controversial
[16-19]. The outcome of liver resection combined with
thrombectomy for 56 HCC patients with PVTT were
retrospectively studied. The overall hospital death was
1.8%. This proved that the surgical treatment for HCC
patients with PVTT was safe. A novel classification
was introduced in this study: group A, tumor thrombi
involving the main portal vein trunk or both the left
and right portal veins and group B, tumor thrombi
involving only one branch (left or right) of portal vein
(Figure 1). Group A had more severe blood occlusion
of portal vein system which may develop into portal
hypertension. Interestingly, we found that group A
had more liver cirrhosis than group B (P = 0.047). This
implied that there may have been a relation between
the two factors. The rates of capsular formation and
tumor number showed differences between the two
groups (P = 0.047, P = 0.032). As capsular formation
and tumor number were reported to be the inde-
pendent prognostic factors, we studied the overall
survival rates of the two groups. The 1-year overall
survival rates of group A after liver resection was
31.5%. The 1-, 3-, and 5-year overall survival rates of
group B were 62.3%, 16.1%, and 5.2%, respectively.
For further study, group B had significantly better
overall survival than group A (P = 0.033). We also
investigated the recurrence pattern in the two groups
Figure 2 Overall survival and disease-free survival curves of group A and group B. Group B had significantly better overall and disease-free
survival curves than group A (P = 0.033; P = 0.021).
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significantly higher incidence of recurrence than
group B (P = 0.021). However, there was no significant
difference in recurrence pattern between the two
groups (P = 0.876). Shi et al. introduced a new classi-
fication for HCC with PVTT, with their classifica-
tions; patients were classified into four types: I, II, III,
and IV, each type has two subtypes [17]. In our study,
patients were classified into just two groups: A and B.
Both Shi’s classification and our classification were
based on different prognoses of different groups.
However, our classification was simpler and clearer,
and Shi’s classification was more detailed and more
complex.
The patients with large blood loss (≥1,000) were more
in group A. This may attribute to that the extraction ofFigure 3 Overall survival curves of the subgroups according to Figure
and group C (P = 0.675). There was no significant difference between groutumor thrombus in group A was often by opening the
trunk of portal vein. While in group B, the extraction of
PVTT was often through the broken ends of portal vein.
Postoperative complications of the two groups were
compared. There was no significant difference in com-
plications between the two groups except the ascites
(P = 0.028). This may attribute to that group A had
more liver cirrhosis.
Conclusions
In conclusion, liver resection combined with thrombectomy
for HCC with PVTT is safe and can get better outcome in
HCC patients with PVTT involving only one branch
(left/right) of portal vein compared to patients with
PVTT involving the main portal vein trunk or both
the left and right portal veins.1. There was no significant difference between group A, group B,
p D and group E (P = 0.383).
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